Pfenex Awarded Subcontract by Leidos to Develop Malaria Antigen
Pfenex receives subcontract from Leidos to develop a production process for the malaria antigen Plasmodium falciparum reticulocyte-binding homolog 5 (Rh5).
Pfenex reports that Leidos Holdings (formerly SAIC) a provider of scientific engineering systems integrations on technical services, has awarded Pfenex a subcontract to develop a robust, scalable, cGMP-ready production process for large-scale production of the blood-stage malaria antigen Plasmodium falciparum reticulocyte-binding homolog 5 (Rh5). This contract is a result of successful preclinical studies performed by Leidos collaborators to evaluate the Rh5 antigen that was produced using the Pfēnex Expression Technology platform. The subcontract is funded with federal funds from Leidos’ prime Malaria Vaccine Production and Support Services contract from the National Institute of Allergy and Infectious Diseases (NIAID)
This is the second subcontract awarded to Pfenex for the development of hard-to-express malaria antigens. Leidos had previously awarded Pfenex a subcontract to develop a scalable, cGMP-ready production process for large-scale production of full-length circumsporozoite protein from P. falciparum. Pfenex will commence process development activities while continuing to provide materials to Leidos and NIAID for ongoing preclinical studies.
Source: Pfenex
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
